One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018 by Melissa Healy, Los Angeles Times
PET scan of a human brain with Alzheimer's disease. Credit: public domain

To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

An experimental called idalopirdine failed to help people with mild to moderate Alzheimer's disease in a trio of that involved 2,525 patients in 34 countries. Not only did the drug fail to bring about any meaningful change in cognitive tests that are widely used in diagnosing and tracking the progress of the disease, it also failed to cause significant improvements in general measures of daily function among those taking it at any of three tested doses.

Those are relatively modest goals—not to reverse Alzheimer's disease or block its progress, but simply to slow the loss of function in those who have it. Even that, it turns out, is a humbling challenge.

The failure of idalopirdine, reported Tuesday in the Journal of the American Medical Association, probably marks the unraveling of an approach to Alzheimer's treatment that has long looked promising.

The experimental drug largely acted to increase the supply of the brain chemical serotonin, which, among other things, regulates mood, sleep and appetite, and ebbs in those with Alzheimer's disease. Idalopirdine also acts on four other neural transmitters that are affected by Alzheimer's: glutamate, norepinephrine, acetylcholine and dopamine.

The drug had looked promising in earlier clinical trials that focused largely on safety. But after 24 weeks, subjects with Alzheimer's who got idalopirdine fared no better than those who got a sham drug.

The disappointing results follow the failure, reported last fall, of intepirdine, another that acted on many of the same brain systems as idalopirdine.

Subjects in both trials also took donepezil (long marketed as Aricept) or another Alzheimer's drug in the same class. Researchers had hoped that the combination therapy might boost the action of several different neurotransmitter systems at once to improve mental function in Alzheimer's patients.

Lundbeck, the publicly traded Danish pharmaceutical company that was developing idalopirdine, told investors last year that it would not be asking the Food & Drug Administration to evaluate the drug for the U.S. market. That would have been the next step if the phase 3 trials had succeeded.

As researchers and government officials have focused on ambitious efforts to reverse or even cure Alzheimer's, doctors have appealed for therapies that will at least improve the lives of the 5.5 million Americans already living with the disease.

Yet the new results underscore the diabolical challenge of merely slowing Alzheimer's disease once its behavioral symptoms become evident, according to Dr. David A. Bennett, a neurologist and director of Rush University's Alzheimer's Disease Center in Chicago.

Given the millions of Americans already afflicted, "better symptomatic therapies must continue to be pursued," Bennett wrote in an editorial also published in JAMA. "However, from a public health perspective, delaying the onset of Alzheimer disease dementia is the most effective approach to reduce the overall human and economic toll of the disease."

That, he wrote, will require earlier diagnosis of Alzheimer's among a broader range of people, including people with no outward sign of dementia. And those in the disease's earliest phases will need to be enrolled in of preventive strategies faster, and in larger numbers.

A public hungry for quick fixes and streamlined drug development had better get patient, Bennett added. Citing a recent exploration of why so many Alzheimer's disease drugs fail, he noted that treatments that could halt or reverse Alzheimer's might need to be tested for five to 10 years for an effect to be detected. Currently, few such trials last for more than three years.

And maybe, Bennett added, we're not seeing that we're on a trajectory—albeit a long one—to eventual success.

"Given the series of failures in rigorous attempts to develop an effective treatment for Alzheimer disease, it may seem difficult to be optimistic," he wrote. "Yet lessons from the past century paint a different picture."

With a request for $100 million in added funds for cancer research in 1971, President Richard Nixon began a process of investment and discovery that has brought forth treatments for cancer that were beyond imagination at the time. In 2011, President Barack Obama launched the National Alzheimer's Project Act with an initial investment of $50 million. By 2017, federal research on Alzheimer's disease had reached $1.4 billion.

"It is just a matter of time before that knowledge is translated into effective strategies for the treatment and prevention" of Alzheimer's, Bennett wrote.

And none too soon: The Alzheimer's Association estimates that an American is newly diagnosed with the every 66 seconds.

Explore further: New forecast shows 6 million with Alzheimer's disease, cognitive impairment

Related Stories

New forecast shows 6 million with Alzheimer's disease, cognitive impairment

December 8, 2017
Using new methodology, scientists calculate that approximately 6 million American adults have Alzheimer's disease or mild cognitive impairment, which can sometimes be a precursor to the disease. The estimate, funded by the ...

Population of Americans with Alzheimer's will more than double by 2060, study shows

December 7, 2017
About 15 million Americans will have either Alzheimer's dementia or mild cognitive impairment by 2060, up from approximately 6.08 million this year, according to a new study by researchers at the UCLA Fielding School of Public ...

Pfizer and J&J end development of Alzheimer's drug

August 6, 2012
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.

Past failures pave way for promising new Alzheimer's treatments

June 3, 2015
Since 2002, close to 300 drug candidates to treat Alzheimer's have run into clinical dead ends. But now, having learned from those failures, researchers are testing—and retesting—a batch of the most promising compounds ...

Merck halts trial of once 'promising' Alzheimer's drug

February 15, 2017
US pharmaceutical giant Merck announced it is halting a clinical trial on a drug once touted as a promising treatment for Alzheimer's disease, saying studies show it does not work.

27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next five years

July 18, 2017
Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer's pipeline analysis presented today at the Alzheimer's ...

Recommended for you

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

Mice with frequent flier miles advance the Alzheimer's cause

January 4, 2018
Alzheimer's disease wreaks emotional havoc on patients, who are robbed of their memories, their dignity, and their lives. It's financially devastating as well: care for Alzheimer's patients is predicted to top $1 trillion ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.